Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4 , with Non-GAAP Net Profit of $1.4 million Completed $325 million capital return program, reducing shares outstanding by 37% Ampreloxetine investor event planned for Q2 2024 DUBLIN Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023 "The Theravance team delivered a strong performance in 2023, having achieved our financial objectives in the fourth quarter and exceeded our aggressive annual goal for YUPELRI hospital growth," said Rick E Winningham, Chief Executive Officer. " We look forward to continuing YUPELRI net sales growth in 2024 and completing enrollment in the CYPRESS study in the second half of this year. Further, we are ex
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma, Inc. (NASDAQ: TBPH) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.MarketBeat
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 [YahooYahoo
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024PR Newswire
- Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
TBPH
Earnings
- 2/26/24 - Miss
TBPH
Sec Filings
- 4/5/24 - Form DEF
- 4/4/24 - Form 4
- 4/4/24 - Form 4
- TBPH's page on the SEC website